Chu K C, Horm J W, Smart C R
Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, MD 20892.
Public Health Rep. 1990 Jan-Feb;105(1):36-46.
A method to estimate site-specific cancer mortality rates using Surveillance, Epidemiology, and End Results (SEER) Program incidence and survival data is proposed, calculated, and validated. This measure, the life table-derived mortality rate (LTM), is the sum of the product of the probability of being alive at the beginning of an interval times the probability of dying of the cancer of interest during the interval times the annual age-adjusted incidence rate for each year that data have been collected. When the LTM is compared to death certificate mortality rates (DCM) for organ sites with no known misclassification problems, the LTM was within 10 percent of the death certificate rates for 13 of 14 organ sites. In the sites that have problems with the death certificate rates, there were major disagreements between the LTM and DCM. The LTM was systematically lower than the DCM for sites if there was overreporting on the death certificates, and the LTM was higher than the DCM for sites if there was underreporting. The limitations and applications of the LTM are detailed.
提出、计算并验证了一种使用监测、流行病学和最终结果(SEER)计划的发病率和生存数据来估计特定部位癌症死亡率的方法。这种测量方法,即生命表衍生死亡率(LTM),是在数据收集的每一年中,区间开始时存活概率乘以该区间内死于所关注癌症的概率再乘以年龄调整后的年发病率之积的总和。当将LTM与无已知错误分类问题的器官部位的死亡证明死亡率(DCM)进行比较时,14个器官部位中有13个部位的LTM在死亡证明率的10%以内。在死亡证明率存在问题的部位,LTM和DCM之间存在重大差异。如果死亡证明存在报告过度的情况,LTM会系统地低于DCM;如果存在报告不足的情况,LTM会高于DCM。详细介绍了LTM的局限性和应用。